One Year Drug Treatment in First-Episode Schizophrenia

Summary

Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.

Conditions

• Schizophrenia

Interventions

DRUG

Haloperidol, Risperidone (drug)

targeted dose of 2-4 mg/day over 1 year

Sponsors & Collaborators

• German Federal Ministry of Education and Research

  collaborator OTHER_GOV

• German Research Network On Schizophrenia

  collaborator NETWORK

• Janssen-Cilag Ltd.

  collaborator INDUSTRY

• University of Bonn

  collaborator OTHER

• Humboldt-Universität zu Berlin

  collaborator OTHER

• University of München

  collaborator OTHER

• University of Göttingen

  collaborator OTHER

• University of Cologne

  collaborator OTHER

• Mainz University

  collaborator OTHER

• University Hospital Tuebingen

  collaborator OTHER

• Universität Duisburg-Essen

  collaborator OTHER

• University of Mannheim

  collaborator OTHER

• University of Jena

  collaborator OTHER

• Martin-Luther-Universität Halle-Wittenberg

  collaborator OTHER

• RWTH Aachen University

  collaborator OTHER

• University of Wuerzburg

  collaborator OTHER

• Heinrich-Heine University, Duesseldorf

  lead OTHER

Principal Investigators

• Wolfgang Gaebel, Professor · Department of Psychiatry and Psychotherapy, University of Duesseldorf

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2000-11-30

Primary Completion

2005-06-30

Completion

2005-06-30

Countries

• Germany

Study Locations